De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
CRISPR Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO CRISPR Therapeutics' is Sam Kulkarni, benoemd in Dec2017, heeft een ambtstermijn van 6.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.32M, bestaande uit 5.9% salaris en 94.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde $ 14.48M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 5.3 jaar.
Belangrijke informatie
Sam Kulkarni
Algemeen directeur
US$12.3m
Totale compensatie
| Percentage CEO-salaris | 5.9% |
| Dienstverband CEO | 6.8yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 5yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$266m |
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$12m | US$725k | -US$154m |
| Sep 30 2023 | n/a | n/a | -US$354m |
| Jun 30 2023 | n/a | n/a | -US$416m |
| Mar 31 2023 | n/a | n/a | -US$524m |
| Dec 31 2022 | US$21m | US$700k | -US$650m |
| Sep 30 2022 | n/a | n/a | -US$681m |
| Jun 30 2022 | n/a | n/a | -US$633m |
| Mar 31 2022 | n/a | n/a | US$312m |
| Dec 31 2021 | US$17m | US$670k | US$378m |
| Sep 30 2021 | n/a | n/a | US$412m |
| Jun 30 2021 | n/a | n/a | US$447m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$9m | US$625k | -US$349m |
| Sep 30 2020 | n/a | n/a | -US$211m |
| Jun 30 2020 | n/a | n/a | US$20m |
| Mar 31 2020 | n/a | n/a | US$46m |
| Dec 31 2019 | US$16m | US$550k | US$67m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$200m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$10m | US$518k | -US$165m |
| Sep 30 2018 | n/a | n/a | -US$117m |
| Jun 30 2018 | n/a | n/a | -US$91m |
| Mar 31 2018 | n/a | n/a | -US$75m |
| Dec 31 2017 | US$7m | US$405k | -US$68m |
Compensatie versus markt: De totale vergoeding ($USD 12.32M ) Sam } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).
Compensatie versus inkomsten: De vergoeding van Sam is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sam Kulkarni (46 yo)
6.8yrs
Tenure
US$12,322,196
Compensatie
Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 6.8yrs | US$12.32m | 0.35% $ 14.0m | |
| Chief Financial Officer | 1.6yrs | US$5.91m | 0.011% $ 453.8k | |
| General Counsel & Secretary | 7.4yrs | US$3.51m | 0.069% $ 2.8m | |
| Founder | no data | geen gegevens | geen gegevens | |
| Co-Founder & Scientific Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Scientific Founder | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Chief Operating Officer | less than a year | geen gegevens | 0.016% $ 627.7k | |
| Head of Technical Operations | 5yrs | geen gegevens | geen gegevens | |
| Vice President of Corporate Communications & Investor Relations | no data | geen gegevens | geen gegevens |
5.0yrs
Gemiddelde duur
49yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CRSP is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 6.3yrs | US$12.32m | 0.35% $ 14.0m | |
| Co-Founder & Scientific Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Scientific Founder & Advisory Board Member | no data | geen gegevens | geen gegevens | |
| Lead Independent Director | 4.3yrs | US$552.56k | 0.0023% $ 90.8k | |
| Independent Director | 9.5yrs | US$545.06k | 0.00031% $ 12.4k | |
| Independent Director | 5.3yrs | US$532.56k | 0% $ 0 | |
| Independent Director | 9.5yrs | US$542.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.3yrs | US$555.06k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$536.24k | 0% $ 0 |
5.3yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CRSP wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).